芪参益气滴丸对心肌梗死大鼠的作用机制及心肌保护研究
该研究将60只健康雄性SD大鼠随机分为假手术组、模型组和观察组(每组20只),通过结扎左冠状动脉前降支建立急性心肌梗死模型。观察组造模后给予芪参益气滴丸0.135 g/kg灌胃,假手术组和模型组给予等量生理盐水,每日一次连续28天。结果显示,与模型组相比,观察组血清炎症因子(LTB4、PGE2、TNF-α、IL-6)、左心室舒张末压、心脏重量/体重比值、左心室重量/心脏重量比值、心肌梗死面积、心肌炎症因子mRNA和蛋白表达、TGF-β/Smads通路相关蛋白及Bax蛋白表达均显著降低,而左心室收缩压、±dp/dt max和Bcl-2蛋白表达显著升高(均P<0.05)。HE和Masson染色显示观察组心肌病理改变和纤维化程度较模型组明显改善。结论认为芪参益气滴丸可通过TGF-β/Smads通路减轻心肌纤维化、抑制心室重构,并通过降低cPLA2抑制炎症因子释放、上调Bcl-2和下调Bax抑制凋亡来减轻心肌损伤。
要点
- 在结扎左冠状动脉前降支的SD大鼠心肌梗死模型中,芪参益气滴丸0.135 g/kg每日一次灌胃28天,使心肌梗死面积从模型组的(44.98±1.52)%降至(27.21±2.87)%(P<0.05)。
- 观察组左心室舒张末压为(-2.03±2.98)mmHg,低于模型组的(7.03±1.39)mmHg;左心室收缩压为(129.01±11.93)mmHg,高于模型组的(108.11±12.69)mmHg(均P<0.05)。
- 观察组血清LTB4为(370.11±46.98)ng/L、PGE2为(48.75±26.35)ng/L、TNF-α为(177.28±22.65)μg/L、IL-6为(493.22±165.99)μg/L,均低于模型组(均P<0.05)。
- 观察组心脏重量/体重比值为(6.53±0.11)%、左心室重量/心脏重量比值为(0.26±0.01),均低于模型组的(7.14±0.24)%和(0.32±0.02)(均P<0.05)。
- 机制上,芪参益气滴丸降低心肌cPLA2、COX-2、5-LOX表达及TGF-β/Smads通路相关蛋白表达,上调Bcl-2、下调Bax蛋白表达(均P<0.05)。
适用人群与场景
- 健康清洁级雄性Sprague-Dawley(SD)大鼠,共60只,随机分为假手术组、模型组和观察组,每组20只。
- 急性心肌梗死模型通过结扎左冠状动脉前降支建立;假手术组和模型组给予等量生理盐水。
处置流程与药物剂量
- 观察组造模后给予芪参益气滴丸0.135 g/kg灌胃,每日一次,连续28天;假手术组和模型组给予等量生理盐水。
研究设计与关键结果
- 研究类型为动物实验,60只雄性SD大鼠随机分为假手术组、模型组和观察组(每组20只),通过结扎左冠状动脉前降支建立急性心肌梗死模型。
- 与模型组相比,观察组血清LTB4(370.11±46.98 vs. 633.23±83.37 ng/L)、PGE2(48.75±26.35 vs. 131.25±29.75 ng/L)、TNF-α(177.28±22.65 vs. 248.47±16.21 μg/L)、IL-6(493.22±165.99 vs. 638.41±191.66 μg/L)均显著降低(均P<0.05)。
- 与模型组相比,观察组左心室舒张末压(-2.03±2.98 vs. 7.03±1.39 mmHg)降低,左心室收缩压(129.01±11.93 vs. 108.11±12.69 mmHg)、+dp/dt max(3101.3±378.6 vs. 2105.3±245.9 mmHg/s)、-dp/dt max(2612.4±249.7 vs. 1654.4±188.1 mmHg/s)升高(均P<0.05)。
- 与模型组相比,观察组心脏重量/体重比值(6.53±0.11% vs. 7.14±0.24%)、左心室重量/心脏重量比值(0.26±0.01 vs. 0.32±0.02)、心肌梗死面积(27.21±2.87% vs. 44.98±1.52%)均显著降低(均P<0.05)。
- HE染色显示模型组心肌有明显炎症因子浸润,观察组病理改变较模型组明显改善;Masson染色显示模型组有严重胶原增生,观察组纤维化程度较模型组明显改善。
- 与模型组相比,观察组心肌炎症相关因子(cPLA2、COX-2、5-LOX)mRNA和蛋白表达、TGF-β/Smads通路相关蛋白(TGF-β1、Smad2/3、Collagen I、Collagen III)表达及Bax蛋白表达均显著降低,Bcl-2蛋白表达显著升高(均P<0.05)。
证据类型、等级与局限
- 证据类型:动物实验(大鼠心肌梗死模型)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 该研究为大鼠实验,作者认为芪参益气滴丸可通过TGF-β/Smads信号通路减轻心肌纤维化、抑制心室重构,并通过降低cPLA2抑制炎症因子释放、上调Bcl-2和下调Bax抑制凋亡来减轻心肌损伤。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To approach the mechanisms and myocardial protective effect of Qishen Yiqi dropping pills on rats with myocardial infarction.
METHODS: Sixty clean healthy male Sprague-Dawley (SD) rats were randomly divided into sham operation group, model group and observation group (each n = 20). The rat model of acute myocardial infarction (AMI) was established by ligation of left anterior descent (LAD) branch of coronary artery. After modeling, the rats in observation group were given 0.135 g/kg of Qishen Yiqi dropping pills, and sham operation group and model group were administered the same amount of normal saline, once a day for consecutive 28 days. At the end of treatment, the levels of serum inflammatory factors of leukotriene B4 (LTB4), prostaglandin E2 (PGE2), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) were measured by enzyme linked immunosorbent assay (ELISA); the changes of the indexes of hemodynamic [left ventricular systolic pressure (LVSP), left ventricular end-diastolic pressure (LVEDP), the maximal rate of increase/decrease in left ventricular pressure (±dp/dt max)], the ratio of the heart weight/body weight, and the ratio of the left ventricular weight/heart weight (LVW/HW), the myocardial infarction area, myocardial histopathological changes were observed in the three groups; myocardial tissues inflammatory related factors [the mRNA and protein expressions of cytosolic phospholipase A2 (cPLA2), cyclooxygenase-2 (COX-2), 5-lipoxygenase (5-LOX)], and the expression levels of transforming growth factor-β (TGF-β)/Smads signal transduction pathway related protein (TGF-β1, Smad2/3, Collagen I, Collagen III) and cell apoptosis related factors (Bcl-2, Bax) protein were measured.
RESULTS: Compared with the sham operation group, levels of serum inflammatory factors, the index of LVEDP, the ratio of the heart weight/body weight, LVW/HW, myocardial infarction area, the mRNA and protein expression levels of inflammatory factors in myocardium, the expression levels of TGF-β/Smads signal transduction pathway related protein and the cell apoptosis related factors protein in model group were all significantly elevated, while LVSP and ±dp/dt max were obviously decreased in model group. Compared with the model group, the levels of inflammatory factor in serum [LTB4 (ng/L): 370.11±46.98 vs. 633.23±83.37, PGE2 (ng/L): 48.75±26.35 vs. 131.25±29.75, TNF-α (μg/L): 177.28±22.65 vs. 248.47±16.21, IL-6 (μg/L): 493.22±165.99 vs. 638.41±191.66], LVEDP [mmHg (1 mmHg = 0.133 kPa): -2.03±2.98 vs. 7.03±1.39], the ratio of the heart weight/body weight [(6.53±0.11)% vs. (7.14±0.24)%], LVW/HW (0.26±0.01 vs. 0.32±0.02), myocardial infarction area [(27.21±2.87)% vs. (44.98±1.52)%], mRNA and protein expression of myocardial inflammatory factors, the expression of TGF-β/Smads signal transduction pathway related protein, and the protein expression of Bax were all significantly decreased in observation group (all P < 0.05), LVSP (mmHg: 129.01±11.93 vs. 108.11±12.69), the +dp/dt max (mmHg/s: 3 101.3±378.6 vs. 2 105.3±245.9), the -dp/dt max (mmHg/s: 2 612.4±249.7 vs. 1 654.4±188.1), while the protein expression of Bcl-2 in observation group were obviously increased (all P < 0.05). It was demonstrated by hematoxylin-eosin (HE) staining that there were no obvious pathological changes in the sham operation group; obvious infiltration of inflammatory factors in myocardium was shown in model group; pathological changes in the observation group were significantly improved as compared with those in the model group. It was shown by Masson staining that there were slight hyperplasia of myocardial fibers and no obvious pathological changes in the sham operation group. Severe collagen hyperplasia was found in model group, and the degree of fibrosis in the observation group was significantly improved.
CONCLUSIONS: Qishen Yiqi dropping pills can reduce the degree of myocardial fibrosis and inhibit the ventricular remodeling via TGF-β/Smads signal transduction pathway. The dropping pills can also suppress the release of inflammatory factors by reducing cPLA2 to decrease the inflammatory response and inhibit apoptosis and alleviate myocardial injury by up-regulating the expression of Bcl-2 and down-regulating the expression of Bax.
参考来源
- Yang Q, Cao Y. [Study on mechanisms and myocardial protective effect of Qishen Yiqi dropping pills on rats with myocardial infarction]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017. PMID: 28625237. doi:10.3760/cma.j.issn.2095-4352.2017.06.005
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。